Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - DoubtfulReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exponent (EXPO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Exponent (EXPO) over the last 16 years, with Q4 2025 value amounting to $358.6 million.

  • Exponent's Total Liabilities rose 742.89% to $358.6 million in Q4 2025 from the same period last year, while for Oct 2025 it was $358.6 million, marking a year-over-year increase of 742.89%. This contributed to the annual value of $356.2 million for FY2025, which is 2253.59% up from last year.
  • Exponent's Total Liabilities amounted to $358.6 million in Q4 2025, which was up 742.89% from $331.7 million recorded in Q3 2025.
  • In the past 5 years, Exponent's Total Liabilities ranged from a high of $358.6 million in Q4 2025 and a low of $199.4 million during Q2 2021
  • Its 5-year average for Total Liabilities is $269.9 million, with a median of $252.0 million in 2023.
  • In the last 5 years, Exponent's Total Liabilities crashed by 277.64% in 2023 and then surged by 3414.58% in 2024.
  • Over the past 5 years, Exponent's Total Liabilities (Quarter) stood at $266.7 million in 2021, then decreased by 0.29% to $265.9 million in 2022, then grew by 9.32% to $290.7 million in 2023, then rose by 14.83% to $333.8 million in 2024, then rose by 7.43% to $358.6 million in 2025.
  • Its last three reported values are $358.6 million in Q4 2025, $331.7 million for Q3 2025, and $321.8 million during Q2 2025.